210 related articles for article (PubMed ID: 28192086)
1. Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments.
Hampel KJ; de Abreu FB; Sidiropoulos N; Peterson JD; Tsongalis GJ
Exp Mol Pathol; 2017 Apr; 102(2):215-218. PubMed ID: 28192086
[TBL] [Abstract][Full Text] [Related]
2. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.
Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R
PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674
[TBL] [Abstract][Full Text] [Related]
3. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics.
Misyura M; Zhang T; Sukhai MA; Thomas M; Garg S; Kamel-Reid S; Stockley TL
J Mol Diagn; 2016 Nov; 18(6):842-850. PubMed ID: 27770852
[TBL] [Abstract][Full Text] [Related]
5. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.
Singh RR; Patel KP; Routbort MJ; Reddy NG; Barkoh BA; Handal B; Kanagal-Shamanna R; Greaves WO; Medeiros LJ; Aldape KD; Luthra R
J Mol Diagn; 2013 Sep; 15(5):607-22. PubMed ID: 23810757
[TBL] [Abstract][Full Text] [Related]
6. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory.
Strom CM; Rivera S; Elzinga C; Angeloni T; Rosenthal SH; Goos-Root D; Siaw M; Platt J; Braastadt C; Cheng L; Ross D; Sun W
PLoS One; 2015; 10(8):e0136419. PubMed ID: 26295337
[TBL] [Abstract][Full Text] [Related]
8. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
[TBL] [Abstract][Full Text] [Related]
9. Effective quality management practices in routine clinical next-generation sequencing.
de Abreu FB; Peterson JD; Amos CI; Wells WA; Tsongalis GJ
Clin Chem Lab Med; 2016 May; 54(5):761-71. PubMed ID: 26872315
[TBL] [Abstract][Full Text] [Related]
10. Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations.
Tsongalis GJ; Peterson JD; de Abreu FB; Tunkey CD; Gallagher TL; Strausbaugh LD; Wells WA; Amos CI
Clin Chem Lab Med; 2014 May; 52(5):707-14. PubMed ID: 24334431
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.
Deak KL; Jackson JB; Valkenburg KC; Keefer LA; Robinson Gerding KM; Angiuoli SV; Datto MB; McCall SJ
J Mol Diagn; 2021 Oct; 23(10):1324-1333. PubMed ID: 34314880
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA.
Kotoula V; Lyberopoulou A; Papadopoulou K; Charalambous E; Alexopoulou Z; Gakou C; Lakis S; Tsolaki E; Lilakos K; Fountzilas G
PLoS One; 2015; 10(6):e0128818. PubMed ID: 26039550
[TBL] [Abstract][Full Text] [Related]
15. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.
Kadri S; Long BC; Mujacic I; Zhen CJ; Wurst MN; Sharma S; McDonald N; Niu N; Benhamed S; Tuteja JH; Seiwert TY; White KP; McNerney ME; Fitzpatrick C; Wang YL; Furtado LV; Segal JP
J Mol Diagn; 2017 Jan; 19(1):43-56. PubMed ID: 27836695
[TBL] [Abstract][Full Text] [Related]
16. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
[TBL] [Abstract][Full Text] [Related]
17. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
18. Inter-laboratory evaluation of SNP-based forensic identification by massively parallel sequencing using the Ion PGM™.
Eduardoff M; Santos C; de la Puente M; Gross TE; Fondevila M; Strobl C; Sobrino B; Ballard D; Schneider PM; Carracedo Á; Lareu MV; Parson W; Phillips C
Forensic Sci Int Genet; 2015 Jul; 17():110-121. PubMed ID: 25955683
[TBL] [Abstract][Full Text] [Related]
19. A Model Study of In Silico Proficiency Testing for Clinical Next-Generation Sequencing.
Duncavage EJ; Abel HJ; Merker JD; Bodner JB; Zhao Q; Voelkerding KV; Pfeifer JD
Arch Pathol Lab Med; 2016 Oct; 140(10):1085-91. PubMed ID: 27388684
[TBL] [Abstract][Full Text] [Related]
20. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
